Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Infographic: Are data blind spots putting your launch at risk?

July 16, 2026 |  

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize opportunities, and optimize commercial strategy.​

InConcert™ brings together omnichannel, field, clinical, and predictive insights in a single decision-making environment – helping commercial teams make smarter, faster decisions backed by Intelligent Commercialization™.

- PMLiVE

Discover how InConcert™ supports commercial launch planning​

If you’re looking for a quick, easy-to-understand overview of InConcert™, this one-page guide is the perfect place to start.​

In just a few minutes, you’ll discover:​

  • The commercial challenge the solution is designed to solve.​
  • How it enables intelligent launch planning.​
  • The four intelligence capabilities that power InConcert™.​
  • The value it delivers for commercial and launch teams.​
  • How it helps organizations make more informed launch decisions.​

Whether you’re exploring InConcert™ for the first time or introducing it to key stakeholders, this concise overview explains everything you need to know – all on a single page.

Download now. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…

Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam

Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam

Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards

Brighton consultancy adds top honour to its award wins

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from…

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards…